ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development
Collaboration will expand access to high sensitivity NULISA immunoassays for clinical biomarker analysis.
ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a leader in ultra-sensitive immunoassay technologies, today announced a partnership in the development of customized biomarker assay solutions using Alamar’s NULISA™ (Nucleic Acid Linked Immuno-Sandwich Assay) immunoassay platform and ARGO™ HT System. This collaboration aims to provide advanced tools for the detection and quantification of critical biomarkers to support neurological disease therapeutic development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241027884281/en/
ADx NeuroSciences logo (Graphic: Business Wire)
Under the terms of the partnership, Alamar Biosciences and ADx NeuroSciences will combine their respective expertise to provide tailored assay solutions to meet the specific needs of pharmaceutical companies advancing novel therapeutics for neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS.
"We are excited to partner with ADx NeuroSciences, a recognized leader in the field of neurodegenerative biomarker research," said Dr. Yuling Luo, Chairman and CEO of Alamar Biosciences. "By combining our NULISA platform's ultra-sensitive detection capabilities with ADx’s extensive expertise in neuroscience antibody and assay development, we aim to accelerate the development of biomarker assays that can facilitate the development and approval of disease modifying therapies for neurodegenerative diseases.”
Koen Dewaele, CEO of ADx NeuroSciences, commented, "Our collaboration with Alamar Biosciences marks a significant step forward in our mission to support pharmaceutical companies advancing their therapeutic programs. Every phase in the search for a therapeutic, from preclinical work up to the launch of the ultimate drug, requires specific biomarker tools. By working with various technology platforms, we are able to make our biomarker assays available on the right technology at the right time. By adding the NULISA platform with its remarkable sensitivity to our range of possible platforms, it enforces our capabilities to support our pharma network in their search for tailor-made biomarkers."
This strategic collaboration highlights both companies' commitment to advancing biomarker detection and expanding the possibilities for early diagnosis and treatment of neurodegenerative diseases. By harnessing the power of the NULISA platform, Alamar Biosciences and ADx NeuroSciences aim to deliver cutting-edge solutions that will benefit clinical research and aid in the development of novel therapeutics.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO™ HT System works seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the high sensitivity protein detection technologies on the market today. For more information, please visit alamarbio.com.
About ADx NeuroSciences NV
ADx NeuroSciences is specialized in the research and development of neurodegenerative biomarker tools for diseases such as Alzheimer's and Parkinson's. Its expertise is used by pharmaceutical and diagnostic companies across the world for the conception, development, production, and worldwide commercialization of novel biomarkers, supporting the development of promising drugs, either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays can be applied to a variety of platforms from research up to IVD use. The company was founded in 2011 and was acquired in 2022 by Fujirebio, a member of H.U. Group Holdings Inc., which is listed on the Tokyo Stock Exchange (TSE: 4544). For more information, please visit www.adxneurosciences.com.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality IVD testing with more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products. Fujirebio was the first company to develop and market CSF biomarkers for AD testing, under the Innogenetics brand, over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated neurodegenerative disease assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools. For more information, please visit www.fujirebio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241027884281/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports First Quarter 2025 Results6.5.2025 22:35:00 CEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2025. Management Commentary “IFF delivered solid first quarter results, driven by disciplined execution and broad-based growth across most of our business,” said IFF CEO Erik Fyrwald. “Our growth, combined with ongoing productivity initiatives, contributed to a meaningful increase in profitability. We also successfully completed the divestiture of our Pharma Solutions business two months ahead of schedule, a key milestone that supports the achievement of our targeted debt leverage ratio." “As we navigate the heightened macroeconomic uncertainty in today’s environment, we remain focused on what we can control - collaborating with our customers to drive growth, investing in innovation and delivering increased productivity. We are maintaining our full-year financial guidance ranges but recognize that the uncertain environment has potential for more challenges, yet we remain confident in our long-term strategy
Lattice to Showcase Advanced Edge AI Solutions at New-Tech 2025 Exhibition6.5.2025 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it will showcase its latest FPGA technology at the New-Tech 2025 Exhibition. Lattice technology demos will be featured in the Telsys Ltd. booth, showcasing industry-leading low power, small form factor FPGAs and application-specific solutions enabling advanced embedded vision, artificial intelligence, and sensor fusion capabilities. Additionally, Lattice will deliver a technical presentation titled “Power-Efficient Robotics and Automation Fueled by Lattice FPGA Technology” about how advanced, power-optimized FPGAs can dramatically reduce power consumption for next-generation automation and robotics solutions for Industrial applications. Who: Lattice Semiconductor What / When: May 20 – 21: Lattice demo showcase (Telsys Ltd. Booth #67-68) May 21, 10:20 a.m.: “Power-Efficient Robotics and Automation Fueled by Lattice Semiconductor FPGA Technology” technical presentation Where: New-Tech 2025 Exhib
Rockstar Games Releases Trailer 2 for Grand Theft Auto VI6.5.2025 18:37:00 CEST | Press release
Explore Vice City and beyond at rockstargames.com/VI Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is proud to announce the release of Trailer 2 for Grand Theft Auto VI, alongside a closer look at the biggest, most immersive evolution of the series yet: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506495901/en/ Set to launch on May 26, 2026, on PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems, Grand Theft Auto VI will soon be available for wishlisting on both the PlayStation and Microsoft Stores. Vice City, USA. Jason and Lucia have always known the deck is stacked against them. But when an easy score goes wrong, they find themselves on the darkest side of the sunniest place in America, in the middle of a criminal conspiracy stretching across the state of Leonida — forced to rely on each other more than ever if they want to mak
Monroe Capital, SMBC and MA Financial Launch US$1.7 Billion Middle Market Lending Joint Venture6.5.2025 16:07:00 CEST | Press release
Monroe Capital, Sumitomo Mitsui Banking Corporation (SMBC) and MA Asset Management (part of MA Financial Group, ASX: MAF) today announced the formation of a new joint venture (“JV”), which will invest up to US$1.7 billion in senior secured loans to U.S. middle market borrowers. The JV harnesses the complementary capabilities of the three partnering institutions to establish a differentiated platform focused on the attractive middle market subset of private credit. The JV expects to benefit from broad access to high-quality, proprietary deal flow of first-lien senior-secured loans to established middle market companies, leveraging the loan origination capabilities of Monroe Capital’s direct lending infrastructure, SMBC’s established private credit and sponsor finance platform and MA Financial’s expertise in specialty credit and co-lending. The JV’s investable capital will be provided by Monroe Capital, SMBC and MA Financial (via its managed funds). Monroe Capital is one of the largest l
Sentry Acquires Emerge Tools to Help Developers Ship Better, Faster Mobile Apps6.5.2025 15:00:00 CEST | Press release
Emerge’s suite of tools will help Sentry build the most complete mobile app monitoring solution on the market Sentry, the leading debugging platform for developers, today announced it has acquired Emerge Tools, a prominent provider of mobile app development solutions. Emerge Tools enables teams to deliver smaller, faster and more reliable mobile apps. Its platform powers visual regression testing at OpenAI and app size monitoring at Spotify. Companies like DoorDash have used Emerge to improve app launch speed by 60%, while Duolingo used Emerge to help delete thousands of lines of unnecessary code. According to Statista, “mobile applications are projected to generate more than 613 billion dollars in revenue in 2025”. In a fast growing mobile app landscape, slow loading times, excessive battery drain, and UI instability can lead to negative user sentiment and app abandonment. Emerge Tools directly addresses these challenges by giving developers the ability to proactively identify and res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom